Robert E. Déziel
Nessuna posizione attualmente
Profilo
Robert E.
Déziel has been Vice President of Medicinal Chemistry for MethylGene, Inc. since joining the company in 2003.
He was Senior Director of Research for Neokimia, Inc. and Origenix Technologies, Inc. Dr. Déziel had over 18 years of experience in drug discovery at Boehringer Ingelheim and Bristol-Myers Squibb.
He received a PhD in Organic Chemistry from the University of Montreal.
Precedenti posizioni note di Robert E. Déziel
| Società | Posizione | Fine |
|---|---|---|
| Neokimia, Inc. | Direttore Tecnico/Scientifico/R&S | - |
| Origenix Technologies, Inc. | Direttore Tecnico/Scientifico/R&S | - |
| MIRATI THERAPEUTICS | Corporate Officer/Principal | - |
Formazione di Robert E. Déziel
| University of Montréal | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 3 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
| Neokimia, Inc. | Health Technology |
| Origenix Technologies, Inc. |
- Borsa valori
- Insiders
- Robert E. Déziel
